Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis
- 1 January 1992
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 339 (8787) , 200-205
- https://doi.org/10.1016/0140-6736(92)90004-m
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factorsBlood, 1990
- Results of the mrc myelomatosis trials for patients entered since 1980Hematological Oncology, 1988
- Chemotherapy of myeloma: Drug combinations versus single agents, an overview, and comments on acute leukemia in myelomaHematological Oncology, 1988
- Multiple myeloma treated with high dose intravenous melphalanBritish Journal of Haematology, 1987
- Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.Journal of Clinical Oncology, 1986
- Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in AdultsBritish Journal of Cancer, 1985
- The prognostic value of serum β 2 microglobulin compared with other presentation features in myelomatosisBritish Journal of Cancer, 1985
- Report on the second myelomatosis trial after five years of follow-up.British Journal of Cancer, 1980
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and designBritish Journal of Cancer, 1976